New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCortagen vs Livagen

Cortagen vs Livagen

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityRecovery & Repair
Cortagen
Anti-Aging & Longevity
Livagen
Summary
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
Short peptide half-life; gene regulatory effects persist beyond peptide clearance
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ, IM, Oral
SubQ, Oral
Research
Typical Dose
10 mg SC or IM daily
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Cardioprotective — protects cardiac tissue from ischemic damage
  • Promotes cardiac regeneration and repair
  • Improves vascular endothelium function
  • Reduces atherosclerosis progression
  • Anti-aging effect on heart muscle cells
  • Improves cardiac output and exercise capacity
  • Reduces oxidative stress in cardiovascular tissue
  • May reduce arrhythmia frequency
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Excellent safety profile
  • Mild injection site reactions
  • Rare: transient hypotension
  • Rare: mild arrhythmia at initiation in cardiac patients
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With